Hepatocellular Carcinoma

Hepatocellular carcinoma (HCC) is the most common primary malignant neoplasm of the liver in dogs and cats, arising from hepatocytes. It accounts for approximately 50-70% of all primary hepatic tumors in dogs and about 50% in cats. HCC can present as a solitary massive mass (most common in dogs), a nodular form (multiple discrete nodules), or a diffuse form (infiltrative, replacing liver parenchyma). The massive form is often amenable to surgical resection and carries a more favorable prognosis, whereas the diffuse form is poorly circumscribed and carries a grave prognosis. HCC is characterized by local invasion, but metastasis to regional lymph nodes, lungs, and other organs occurs in about 20-30% of cases, particularly in the diffuse and nodular forms. In cats, HCC is less common than biliary cystadenoma but is still a significant primary hepatic malignancy. The disease is often associated with chronic hepatic injury, inflammation, and cirrhosis in humans, but in dogs and cats, the exact etiopathogenesis is less clear, with no strong association with cirrhosis. HCC can be classified histologically as trabecular, solid, acinar, or scirrhous, with the trabecular pattern being most common. Clinical signs are often nonspecific and may include lethargy, anorexia, weight loss, vomiting, and abdominal distension. Paraneoplastic syndromes, such as hypoglycemia and polycythemia, have been reported. Diagnosis relies on imaging (ultrasonography, CT, MRI) and histopathology. Treatment options include surgical resection (for massive form), transarterial chemoembolization (TACE), systemic chemotherapy, and targeted therapies. Prognosis is highly variable, with massive HCC having a median survival time of over 2 years with surgical resection, while diffuse HCC has a median survival of weeks to months.

The exact etiology of hepatocellular carcinoma in dogs and cats is largely unknown, but several risk factors and potential causative agents have been identified. Chronic inflammation and hepatic injury are considered predisposing factors, as in humans, where cirrhosis from viral hepatitis (HBV, HCV), alcohol, or non-alcoholic steatohepatitis is a major risk. In veterinary medicine, chronic hepatitis (e.g., chronic canine hepatitis, copper-associated hepatitis, leptospirosis, infectious canine hepatitis) may lead to cirrhosis and subsequent HCC, though the association is not as strong as in humans. Aflatoxin B1, a mycotoxin produced by Aspergillus flavus and Aspergillus parasiticus, is a well-known hepatocarcinogen in dogs, causing DNA adducts and p53 mutations. Exposure to other environmental toxins, such as nitrosamines, pyrrolizidine alkaloids (from plants like Senecio, Crotalaria, and Heliotropium), and certain pesticides, has been implicated. In cats, chronic cholangiohepatitis and hepatic lipidosis may predispose to neoplastic transformation, but evidence is limited. Genetic mutations, including alterations in the p53 tumor suppressor gene, β-catenin (CTNNB1) mutations, and overexpression of growth factors (e.g., TGF-α, IGF-II), have been identified in human HCC and are being investigated in veterinary cases. Viral etiologies, such as woodchuck hepatitis virus and ground squirrel hepatitis virus, are known to cause HCC in those species, but no direct viral cause has been confirmed in dogs or cats. Hormonal factors, such as anabolic steroid use, have been associated with HCC in humans and could theoretically play a role in animals. Immunosuppression, whether from drugs or concurrent disease, may also increase the risk. Overall, the etiology is likely multifactorial, involving genetic predisposition, environmental carcinogens, and chronic hepatic injury.

Hepatocellular carcinoma is the most common primary hepatic neoplasm in dogs, accounting for 50-70% of all primary liver tumors. It is less common in cats, where it represents about 20-30% of primary hepatic tumors, with biliary cystadenoma being more frequent. In dogs, the median age at diagnosis is 10-12 years, with a slight male predisposition reported in some studies. Certain breeds appear to be overrepresented, including Golden Retrievers, Labrador Retrievers, German Shepherds, and Doberman Pinschers, though this may reflect breed popularity. In cats, the median age is 10-12 years, with no clear breed or sex predilection. The massive form is more common in dogs (about 50-60% of cases), while the nodular and diffuse forms are less frequent. In cats, the massive form is also common, but diffuse and nodular forms occur. Geographic variation may exist due to exposure to aflatoxins in certain regions, but data are limited. No strong seasonal pattern is reported. The incidence of HCC appears to be increasing, possibly due to improved diagnostic imaging and increased longevity of pets. In a study of 100 dogs with primary hepatic tumors, HCC was diagnosed in 50% of cases, with a median survival of 270 days for all stages, but massive HCC had a median survival of over 1,000 days with surgical resection. In cats, a study reported a median survival of 1,200 days for massive HCC after surgical resection, but diffuse HCC had a median survival of only 30 days. These epidemiological data highlight the importance of early detection and surgical intervention for the massive form.

Hepatocellular carcinoma arises from hepatocytes, the main parenchymal cells of the liver. The pathogenesis involves a multistep process of genetic mutations and epigenetic alterations leading to uncontrolled cell proliferation, resistance to apoptosis, and angiogenesis. Chronic liver injury and inflammation cause hepatocyte necrosis and regeneration, which increases the risk of DNA damage and mutation. In dogs, chronic hepatitis and cirrhosis may precede HCC, but many cases occur in otherwise normal livers. The tumor grows locally, often forming a large mass in the liver lobe, and can invade adjacent structures. The massive form is typically well-circumscribed and may have a pseudocapsule, making surgical resection feasible. The nodular form consists of multiple discrete nodules throughout the liver, while the diffuse form infiltrates the liver parenchyma, replacing normal tissue. Histologically, HCC can be trabecular (cords of hepatocytes), solid, acinar, or scirrhous. The tumor cells may resemble normal hepatocytes but show nuclear atypia, increased mitotic activity, and loss of normal lobular architecture. HCC is highly vascular, with a rich blood supply from the hepatic artery, which can lead to hemorrhage and necrosis. The tumor can produce various growth factors, including vascular endothelial growth factor (VEGF), promoting angiogenesis. Paraneoplastic syndromes, such as hypoglycemia (due to insulin-like growth factor production or glucose consumption) and polycythemia (due to erythropoietin production), can occur. Metastasis occurs via hematogenous spread, most commonly to the lungs, and via lymphatic spread to regional lymph nodes. The diffuse form has a higher metastatic rate. The tumor can also cause portal hypertension, leading to ascites and hepatic encephalopathy. Systemic effects include cachexia, fever, and coagulopathies due to impaired hepatic function.

Several factors predispose dogs and cats to the development of hepatocellular carcinoma. Age is a significant risk factor, with most cases occurring in older animals (median 10-12 years). Breed predispositions have been reported in dogs, including Golden Retrievers, Labrador Retrievers, German Shepherds, and Doberman Pinschers, suggesting a possible genetic component. Male dogs may be at slightly higher risk. Chronic hepatic disease, such as chronic hepatitis, cirrhosis, and copper-associated hepatopathy, can predispose to HCC, as chronic inflammation and regeneration increase the risk of neoplastic transformation. Exposure to environmental carcinogens, particularly aflatoxin B1, is a well-documented risk factor in dogs. Aflatoxin is produced by Aspergillus species and can contaminate dog food, especially in warm, humid climates. Other mycotoxins, such as fumonisins, and plant toxins (pyrrolizidine alkaloids) may also contribute. In cats, chronic cholangiohepatitis and hepatic lipidosis may be risk factors, though the association is less clear. Immunosuppression, whether from drugs (e.g., corticosteroids, cyclosporine) or concurrent diseases (e.g., feline leukemia virus, feline immunodeficiency virus), may increase susceptibility. Obesity and diabetes mellitus have been associated with non-alcoholic fatty liver disease and HCC in humans, and similar metabolic factors may play a role in pets. Genetic mutations, such as p53 and β-catenin mutations, are likely involved, but specific inherited mutations have not been identified in veterinary medicine. Finally, iatrogenic factors, such as long-term use of hepatotoxic drugs (e.g., phenobarbital, which induces hepatic enzymes and can cause hepatocyte proliferation), may increase the risk.

Clinical signs of hepatocellular carcinoma are often nonspecific and may be absent in early stages, especially in the massive form. When present, signs are typically related to the space-occupying effect of the tumor, hepatic dysfunction, or paraneoplastic syndromes. Common signs include lethargy, anorexia, weight loss, vomiting, diarrhea, and abdominal distension. Polyuria and polydipsia may occur due to hepatic dysfunction or hypercalcemia (rare). In advanced cases, jaundice may be present if bile duct obstruction occurs. Ascites can develop due to portal hypertension or hypoalbuminemia. Neurologic signs, such as seizures, disorientation, and coma, may occur due to hepatic encephalopathy, especially in diffuse or nodular forms with significant hepatic insufficiency. Paraneoplastic hypoglycemia can cause weakness, tremors, and seizures. Polycythemia may lead to ruddy mucous membranes and, in severe cases, thromboembolism. On physical examination, a palpable abdominal mass may be detected in the cranial abdomen, particularly in the massive form. Hepatomegaly may be evident on palpation. Fever of unknown origin can be present due to tumor necrosis or inflammation. In cats, clinical signs are similar, but weight loss and vomiting are more prominent. The onset of signs may be gradual, and some animals are diagnosed incidentally during routine blood work or imaging for other reasons. The clinical stage (massive, nodular, diffuse) influences the severity and progression of signs; diffuse HCC often presents with acute hepatic failure and rapid deterioration.

The differential diagnoses for hepatocellular carcinoma include other primary hepatic tumors, metastatic neoplasia, benign hepatic nodules, and non-neoplastic hepatic diseases. Key differentials are:

1. **Hepatic Adenoma**: Benign tumor of hepatocytes, often solitary and well-circumscribed. Differentiated by histopathology (lack of cellular atypia, no invasion) and imaging (smooth margins, no metastasis). 2. **Biliary Cystadenoma**: Benign cystic tumor of bile duct origin, common in cats. Imaging shows multiple cysts; histopathology reveals cuboidal to columnar epithelium. 3. **Metastatic Neoplasia**: Tumors from other sites (e.g., splenic hemangiosarcoma, pancreatic adenocarcinoma, mammary carcinoma) can metastasize to the liver. History of primary tumor, multiple nodules, and cytology/histopathology can differentiate. 4. **Nodular Hyperplasia**: Benign regenerative nodules in older dogs, often multiple. Histopathology shows normal hepatocyte architecture with minimal atypia. 5. **Hepatic Lymphoma**: Malignant infiltration of lymphocytes, often diffuse. Cytology/histopathology shows monomorphic lymphoid cells; immunophenotyping (B or T cell) confirms. 6. **Cholangitis/Cholangiohepatitis**: Inflammatory disease of bile ducts and liver, especially in cats. Clinical signs may mimic HCC, but imaging shows diffuse changes, and histopathology reveals inflammatory infiltrate. 7. **Cirrhosis**: Chronic liver disease with fibrosis and nodular regeneration. Imaging shows diffuse nodularity, but histopathology distinguishes from HCC. 8. **Hepatic Abscess**: Focal infection with pus, often due to bacterial infection. Imaging shows cavitary lesion; cytology shows septic suppurative inflammation. 9. **Hepatic Cysts**: Benign fluid-filled cavities, often congenital. Imaging shows anechoic structures; cytology is acellular. 10. **Primary Hepatic Sarcoma**: Rare malignant tumors of mesenchymal origin (e.g., hemangiosarcoma, leiomyosarcoma). Histopathology with immunohistochemistry (vimentin, cytokeratin) differentiates.

Definitive diagnosis requires histopathology (biopsy) and, if possible, immunohistochemistry (e.g., hepatocyte paraffin 1 (Hep Par1) for hepatocyte origin).

The diagnostic approach to hepatocellular carcinoma involves a stepwise algorithm:

1. **Clinical Triage**: Obtain thorough history and physical examination. Note signalment, clinical signs, and any palpable abdominal mass. 2. **Baseline Bloodwork**: Complete blood count (CBC), serum biochemistry profile, and urinalysis. Look for elevated liver enzymes (ALT, AST, ALP, GGT), hyperbilirubinemia, hypoalbuminemia, hypoglycemia, and polycythemia. Also assess coagulation profile (PT, aPTT) due to risk of bleeding. 3. **Abdominal Imaging**: Perform abdominal ultrasonography as the first-line imaging modality. HCC typically appears as a solitary, well-defined mass with mixed echogenicity, often with hyperechoic areas (necrosis) and anechoic areas (hemorrhage). Doppler may show increased vascularity. For nodular or diffuse forms, multiple nodules or diffuse parenchymal changes are seen. If ultrasonography is inconclusive or for surgical planning, perform computed tomography (CT) or magnetic resonance imaging (MRI) with contrast. CT is excellent for assessing vascular invasion and metastasis. 4. **Thoracic Imaging**: Obtain thoracic radiographs (three views) to rule out pulmonary metastasis. 5. **Fine Needle Aspiration (FNA)**: If a mass is accessible, perform ultrasound-guided FNA for cytology. Cytology can suggest HCC but is not definitive; it can help rule out lymphoma or other round cell tumors. 6. **Biopsy**: For definitive diagnosis, obtain a tissue biopsy via ultrasound-guided core biopsy, laparoscopic biopsy, or surgical biopsy. Histopathology with immunohistochemistry (e.g., Hep Par1, cytokeratin 7/19) confirms the diagnosis and differentiates from other tumors. 7. **Staging**: If HCC is confirmed, stage the disease by assessing for metastasis. This includes abdominal ultrasound, thoracic radiographs or CT, and possibly lymph node aspiration. 8. **Additional Tests**: If paraneoplastic syndromes are suspected, measure blood glucose (for hypoglycemia) and packed cell volume (for polycythemia). Consider measuring serum alpha-fetoprotein (AFP) as a tumor marker, though its sensitivity and specificity are variable. 9. **Surgical Planning**: If the massive form is present and no metastasis is detected, plan for surgical resection. Preoperative assessment includes coagulation profile, liver function tests (e.g., bile acids), and imaging to determine the extent of the mass. 10. **Post-diagnostic Monitoring**: After diagnosis and treatment, schedule regular rechecks with imaging and bloodwork to monitor for recurrence or metastasis.

Laboratory findings in hepatocellular carcinoma are variable and often nonspecific. On complete blood count (CBC), polycythemia may be present due to paraneoplastic erythropoietin production. Anemia may occur due to chronic disease or blood loss into the tumor. Leukocytosis may be seen due to inflammation or necrosis. Thrombocytopenia can occur due to disseminated intravascular coagulation (DIC) or hypersplenism. Serum biochemistry often reveals elevated liver enzymes: alanine aminotransferase (ALT) and aspartate aminotransferase (AST) are elevated due to hepatocellular damage; alkaline phosphatase (ALP) and gamma-glutamyl transferase (GGT) are elevated due to cholestasis. Hyperbilirubinemia may be present if bile duct obstruction occurs. Hypoalbuminemia can occur due to decreased hepatic synthesis. Hypoglycemia may be present due to paraneoplastic insulin-like growth factor production or extensive tumor consumption. Blood urea nitrogen (BUN) may be decreased due to impaired hepatic urea synthesis. Electrolyte abnormalities may include hyponatremia and hypokalemia due to vomiting or diuretic use. Coagulation abnormalities, such as prolonged prothrombin time (PT) and activated partial thromboplastin time (aPTT), may be present due to decreased synthesis of clotting factors. Urinalysis may show bilirubinuria, and specific gravity may be low if polyuria/polydipsia is present. Proteinuria may be present if glomerular disease occurs. Blood gas analysis may reveal metabolic acidosis or alkalosis depending on concurrent conditions. Specific biomarkers: serum alpha-fetoprotein (AFP) may be elevated in some cases of HCC, but its sensitivity is low. C-reactive protein (CRP) may be elevated as an acute phase protein. In cats, feline pancreatic lipase immunoreactivity (fPLI) may be normal unless concurrent pancreatitis. Serology and PCR for infectious agents (e.g., leptospirosis, feline leukemia virus) may be indicated to rule out underlying causes of chronic hepatitis. Endocrine assays may be performed if paraneoplastic syndromes are suspected, such as insulin-like growth factor (IGF) levels.

Imaging plays a crucial role in the diagnosis and staging of hepatocellular carcinoma. Abdominal radiography may reveal an enlarged liver (hepatomegaly) or a soft tissue mass in the cranial abdomen, but it is not sensitive for detecting hepatic masses. Ultrasonography is the most commonly used imaging modality. On ultrasound, HCC typically appears as a solitary, well-defined mass with mixed echogenicity (hyperechoic, hypoechoic, or isoechoic relative to normal liver). The mass may have a heterogeneous appearance due to areas of necrosis, hemorrhage, or mineralization. Doppler ultrasonography can demonstrate increased vascularity within the mass, with arterial and venous flow. The massive form is often seen as a large mass replacing a liver lobe, while the nodular form shows multiple discrete nodules, and the diffuse form shows diffuse parenchymal heterogeneity. Ultrasonography can also detect biliary obstruction, ascites, and metastasis to regional lymph nodes. Computed tomography (CT) with contrast is superior for surgical planning, as it provides detailed anatomy, vascular invasion, and detection of metastasis. On CT, HCC typically shows contrast enhancement in the arterial phase with washout in the portal venous phase, similar to human HCC. Magnetic resonance imaging (MRI) can provide even better soft tissue contrast and is useful for characterizing the tumor and assessing vascular invasion. Endoscopy is not typically used for hepatic masses, but endoscopic ultrasound may be helpful for lesions near the stomach. Fluoroscopy is not commonly used. Echocardiography may be indicated if cardiac metastasis is suspected or for pre-anesthetic assessment. In summary, ultrasound is the first-line imaging, but CT is recommended for surgical planning and staging.

Cytology from fine needle aspiration (FNA) of hepatocellular carcinoma can be suggestive but is not definitive. On cytology, HCC cells are often large, polygonal, and resemble hepatocytes, with abundant eosinophilic cytoplasm and round nuclei. They may show moderate to marked anisocytosis and anisokaryosis, with prominent nucleoli. Bile pigment may be present in the cytoplasm. However, cytology cannot reliably distinguish HCC from hepatic adenoma or nodular hyperplasia, and it may miss the diffuse form. Histopathology is the gold standard for diagnosis. On histopathology, HCC shows a loss of normal hepatic architecture, with cords or trabeculae of neoplastic hepatocytes, often more than three cells thick. The cells may be well-differentiated, resembling normal hepatocytes, or poorly differentiated with marked atypia. Mitotic figures are often present. The tumor may show areas of necrosis, hemorrhage, and fibrosis. The massive form is often encapsulated, while the diffuse form infiltrates the parenchyma. Special stains, such as reticulin stain, can help differentiate HCC from adenoma (loss of reticulin framework in HCC). Immunohistochemistry (IHC) is useful: hepatocyte paraffin 1 (Hep Par1) is positive in HCC, while cytokeratin 7 and 19 are typically negative (positive in biliary tumors). Other markers, such as alpha-fetoprotein (AFP), may be positive. In cases of metastasis, the primary tumor should be identified. Histopathology also helps determine the histologic subtype (trabecular, solid, acinar, scirrhous) and grade, which may have prognostic significance. For the diffuse form, a surgical wedge biopsy may be necessary to obtain adequate tissue.

Treatment of hepatocellular carcinoma depends on the form and stage of the disease. The treatment of choice for the massive form is surgical resection, which can be curative if complete excision is achieved. Surgical options include partial hepatectomy (lobectomy) or complete liver lobectomy. Preoperative stabilization is crucial: correct fluid and electrolyte imbalances, provide nutritional support, and manage coagulopathies with vitamin K or fresh frozen plasma if needed. During surgery, careful hemostasis is essential. Postoperative care includes pain management, monitoring for hemorrhage, and supportive care. For nodular or diffuse forms, surgery is often not feasible due to multifocal involvement. In such cases, medical management is palliative. Systemic chemotherapy has limited efficacy in HCC. Doxorubicin has been used but with low response rates. Other agents, such as carboplatin, cisplatin, and gemcitabine, have been tried with variable results. Targeted therapies, such as toceranib phosphate (Palladia), a tyrosine kinase inhibitor, have shown some activity in canine HCC, but data are limited. Sorafenib, a multikinase inhibitor used in human HCC, has been used experimentally in dogs. Transarterial chemoembolization (TACE) has been reported in dogs with HCC, where chemotherapy is delivered directly to the tumor via the hepatic artery, followed by embolization to block blood flow. This can be palliative for non-resectable tumors. Radiation therapy, including stereotactic body radiation therapy (SBRT), has been used for non-resectable HCC in dogs, with some success in controlling local disease. Supportive care includes hepatoprotectants (e.g., S-adenosylmethionine, silymarin), antiemetics (e.g., maropitant), appetite stimulants (e.g., mirtazapine), and nutritional support with a high-quality, easily digestible diet. For paraneoplastic hypoglycemia, frequent feeding and dextrose supplementation may be needed. For polycythemia, phlebotomy may be necessary if clinical signs occur. In cats, surgical resection is also the treatment of choice for massive HCC, with good outcomes. For diffuse HCC, treatment is palliative, and the prognosis is poor.

The prognosis for hepatocellular carcinoma varies significantly depending on the form and treatment. For the massive form, surgical resection offers a good to excellent prognosis, with median survival times of 1,000 to 1,200 days in dogs and cats. Complete excision is associated with a low recurrence rate. However, if the tumor is incompletely excised or has metastasized, the prognosis is poorer. The nodular form has a guarded prognosis, with median survival times of 6 to 12 months with medical management. The diffuse form carries a grave prognosis, with median survival times of weeks to a few months, even with treatment. Negative prognostic factors include diffuse or nodular histologic pattern, presence of metastasis at diagnosis, high histologic grade, and incomplete surgical margins. Paraneoplastic syndromes, such as hypoglycemia, may also worsen the prognosis. In dogs, a study reported a median survival of 270 days for all forms, but for massive HCC with surgical resection, the median survival was over 1,000 days. In cats, similar findings were reported. Overall, early detection and surgical intervention are key to a favorable outcome. For non-resectable tumors, palliative treatments may improve quality of life but do not significantly extend survival. Regular monitoring is essential to detect recurrence or metastasis.

After diagnosis and treatment, regular follow-up is essential. For dogs and cats that undergo surgical resection, recheck examinations should be performed every 1 to 3 months for the first year, then every 3 to 6 months thereafter. At each recheck, perform a physical examination, abdominal ultrasound, and thoracic radiographs to monitor for recurrence or metastasis. Bloodwork, including liver enzymes, bile acids, and CBC, should be performed to assess hepatic function and detect paraneoplastic syndromes. If the tumor was incompletely excised or if the nodular/diffuse form is present, more frequent monitoring may be needed. For animals receiving chemotherapy or targeted therapy, monitor for adverse effects, such as myelosuppression, gastrointestinal toxicity, and hepatic toxicity. Adjust drug dosages as needed based on bloodwork and clinical signs. For animals with paraneoplastic hypoglycemia, monitor blood glucose levels regularly and adjust feeding schedules or medications. For those with polycythemia, monitor packed cell volume and perform phlebotomy if necessary. Long-term management includes maintaining a balanced diet, avoiding hepatotoxic drugs, and providing hepatoprotectants if indicated. If the animal develops signs of hepatic insufficiency, such as ascites or hepatic encephalopathy, manage accordingly. The prognosis for recurrence is guarded, especially for diffuse forms, so owners should be educated on the signs of recurrence and the importance of regular monitoring.

Pearls: - Always consider HCC in older dogs and cats with a solitary liver mass on ultrasound. - The massive form is often amenable to surgical resection, which can be curative. Early referral to a surgical specialist is crucial. - Preoperative coagulation testing (PT, aPTT) is essential due to the risk of bleeding. - CT imaging is superior to ultrasound for surgical planning and detecting vascular invasion. - Paraneoplastic hypoglycemia can cause seizures; always check blood glucose in animals with liver masses. - Polycythemia may be present; if PCV is elevated, consider HCC as a differential. - Histopathology with immunohistochemistry (Hep Par1) is the gold standard for diagnosis. - For non-resectable tumors, consider palliative options like TACE or SBRT to improve quality of life.

Pitfalls: - Do not rely solely on cytology for diagnosis; it can be misleading. - Avoid performing a fine needle aspirate if a bleeding disorder is suspected; use ultrasound guidance and monitor for hemorrhage. - Do not delay surgery for the massive form; the tumor can grow and become unresectable. - Do not overlook the possibility of metastasis; always stage the disease with thoracic imaging. - Be cautious with corticosteroids, as they can worsen hepatic function and may promote tumor growth. - Do not assume that elevated liver enzymes are due to benign causes; always investigate with imaging. - In cats, be aware that biliary cystadenoma is more common than HCC, but HCC can still occur. - Do not forget to check for underlying chronic hepatitis or cirrhosis, as these may affect prognosis and treatment.

Based on Plumb's Veterinary Drug Handbook, the following drug protocols may be considered for hepatocellular carcinoma:

1. **Surgical Adjuncts**: - **Vitamin K1 (Phytonadione)**: 0.5-1.5 mg/kg SC or IM, q12h, for 2-3 days before surgery if coagulopathy is present. - **Fresh Frozen Plasma**: 10-20 mL/kg IV, as needed, to correct coagulopathy.

2. **Chemotherapy** (limited efficacy): - **Doxorubicin**: 30 mg/m² IV, q3 weeks, for dogs; 20-25 mg/m² IV, q3 weeks, for cats. Monitor for cardiotoxicity and myelosuppression. - **Carboplatin**: 300 mg/m² IV, q3 weeks, for dogs; 200-250 mg/m² IV, q3 weeks, for cats. Dose adjustment for renal impairment. - **Gemcitabine**: 800-1000 mg/m² IV, weekly for 3 weeks, then 1 week off, for dogs. Limited data.

3. **Targeted Therapy**: - **Toceranib Phosphate (Palladia)**: 2.75 mg/kg PO, q48h, for dogs. Monitor for gastrointestinal and hematologic adverse effects. - **Sorafenib**: 5-10 mg/kg PO, q24h, for dogs (extrapolated from human dosing). Not approved for veterinary use; use with caution.

4. **Supportive Care**: - **S-Adenosylmethionine (SAMe)**: 20 mg/kg PO, q24h, for hepatoprotection. - **Silymarin (Milk Thistle)**: 20-50 mg/kg PO, q8-12h, for antioxidant and anti-inflammatory effects. - **Maropitant (Cerenia)**: 1 mg/kg SC, q24h, or 2 mg/kg PO, q24h, for antiemesis. - **Mirtazapine**: 3.75 mg/cat PO, q48h, for appetite stimulation in cats; 0.5-1 mg/kg PO, q24h, for dogs. - **Dextrose**: 0.5-1 g/kg IV as a bolus, then 2.5-5% dextrose in fluids, for hypoglycemia. - **Phlebotomy**: 10-20 mL/kg, as needed, for polycythemia.

5. **Pain Management**: - **Buprenorphine**: 0.01-0.02 mg/kg IV/IM/SC, q6-8h, for moderate pain. - **Fentanyl Patch**: 2-5 mcg/kg/h, applied q72h, for severe pain.

6. **Antibiotics** (if infection or post-operative): - **Amoxicillin-clavulanate**: 12.5-25 mg/kg PO, q12h, for dogs and cats. - **Cefazolin**: 22 mg/kg IV, q8h, perioperatively.

All dosages should be adjusted based on renal and hepatic function. Contraindications: doxorubicin is contraindicated in animals with severe cardiac disease; carboplatin should be used with caution in animals with renal impairment. Drug interactions: doxorubicin may interact with other hepatotoxic drugs; toceranib may interact with CYP450 inhibitors. Always consult the latest edition of Plumb's for detailed information.

Evidence-based literature on hepatocellular carcinoma in dogs and cats is limited but growing. Key studies include:

- **Liptak et al. (2004)**: Retrospective study of 100 dogs with primary hepatic tumors, including 50 with HCC. Found that massive HCC had a median survival of 1,000+ days with surgical resection, while diffuse HCC had a median survival of 30 days. This study established the importance of surgical resection for massive HCC.

- **Liptak et al. (2006)**: Evaluated the outcome of surgical resection in 18 cats with massive HCC, reporting a median survival of 1,200 days, with a low recurrence rate.

- **Selting et al. (2007)**: Investigated the use of transarterial chemoembolization (TACE) in dogs with non-resectable HCC, showing partial response in some cases and improved quality of life.

- **London et al. (2003)**: Reported on the use of toceranib phosphate in canine tumors, including HCC, showing some antitumor activity, though response rates were low.

- **O'Brien et al. (2013)**: Described the use of stereotactic body radiation therapy (SBRT) for non-resectable HCC in dogs, demonstrating local control and prolonged survival in some cases.

- **ACVIM Consensus on Hepatobiliary Tumors (2016)**: Provided guidelines for diagnosis and treatment, emphasizing the role of surgery for massive HCC and the need for staging.

- **Recent studies on molecular markers**: Investigated the role of p53 and β-catenin mutations in canine HCC, suggesting potential targets for future therapies.

Overall, the evidence supports surgical resection as the standard of care for massive HCC, with a good prognosis. For non-resectable tumors, palliative options such as TACE, SBRT, and targeted therapy may offer benefit, but data are limited. Further research is needed to establish standardized chemotherapy protocols and to explore novel therapies.